International Society

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Multiply Labs Unveils First Peer-Reviewed Study Showing that Robotic Cell Expansion Can Match the Performance and Reduce the Costs of a Manual Process

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Robotics, Health Technology, Technology, Manufacturing, Automation, Multiplication, Patient, GMP, Cell, Multimedia, Therapy, Organization, ISCT, FDA, Phenotype, International Society, Medical device

View the full release here: https://www.businesswire.com/news/home/20240326888217/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240326888217/en/
    The paper, “ Development of a robotic cluster for automated and scalable cell therapy manufacturing ,” found that during the expansion phase of T cells-based therapy, Multiply Labs’ robotic system can automate an existing manual process while maintaining statistical equivalence on all critical process parameters.
  • In fact, as much as 50% of manufacturing costs stem from labor-intensive manual processes and a shortage of skilled workers.
  • A key advantage of Multiply Labs’ robotic technology is its compatibility with leading cell therapy manufacturing instruments.
  • The data in this study shows that it is possible to automate an existing cell expansion protocol without significantly changing the process or impacting product characteristics.

egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

Retrieved on: 
Tuesday, March 26, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Practice Management, Managed Care, Health, Artificial Intelligence, Bernard Marcus, International Society, Coronary artery disease, Partnership, George Washington University, Patient, Research, Cardiac catheterization, NYU, Treasurer, MD, Society, Amoroso, Medical school, Vinod, Physician, Pharmaceutical industry

egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .

Key Points: 
  • egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .
  • His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.
  • "We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board," said Joel Portice, president and CEO of egnite.
  • The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Tuesday, March 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Optical, Health, International Society, Partnership, DES, ASCRS, Patient, Ophthalmology, Surface, University, Dry, MD, Refraction, Cataract, Eye, Mycophenolic acid, Society, Dry eye syndrome, Lead, Pharmaceutical industry

Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.

Key Points: 
  • Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.
  • A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A.
  • Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.
  • Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

Dr. Adam Rubinstein, MD, Wins 2024 AMWC Best Surgical Body Shaping Award for Total Body and Breast Makeover Post Weight Loss

Retrieved on: 
Thursday, April 4, 2024
College of Medicine, Plastic, International Society, Education, Nova Southeastern University, Weight loss, Social media, Aesthetics, FIU, Aesthetic Plastic Surgery, University, Florida International University, Plastic surgery, Newsweek, Physician, Dentistry

MIAMI, April 4, 2024 /PRNewswire/ -- Esteemed Board-Certified Plastic Surgeon, Dr. Adam J. Rubinstein, has been honored with the 2024 Aesthetic and Anti-Aging Medicine World Congress (AMWC) Best Surgical Body Shaping Award for his exceptional work in total body and breast makeover following weight loss.

Key Points: 
  • MIAMI, April 4, 2024 /PRNewswire/ -- Esteemed Board-Certified Plastic Surgeon, Dr. Adam J. Rubinstein, has been honored with the 2024 Aesthetic and Anti-Aging Medicine World Congress (AMWC) Best Surgical Body Shaping Award for his exceptional work in total body and breast makeover following weight loss.
  • The competition received over 1000 applications, resulting in 237 finalists, 2,400 voters, and over 20,500 votes.
  • Expressing his gratitude, Dr. Adam Rubinstein stated, "I am honored to have received the prestigious AMWC Aesthetic Award for Best Surgical Body Shaping at the Monaco meeting.
  • The AMWC and its attendees, panelists and award winners represent some of the most esteemed doctors in the world.

ISPE Announces 2024 Facility of the Year Awards Submission Finalists

Retrieved on: 
Tuesday, March 12, 2024
Conference, Medication, International Society, Social impact, ISPE, Life, Supply chain, Creativity, Pharma, Pharmaceutical industry

NORTH BETHESDA, Md., March 12, 2024 /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is pleased to announce the 2024 Facility of the Year Awards (FOYA) submission finalists that met the rigorous qualifications and requirements of the FOYA program.

Key Points: 
  • The 2024 Facility of the Year Awards (FOYA) submission finalists are announced at the 2024 ISPE Aseptic Conference, taking place 12-13 March 2024 in Vienna, Austria, and virtually.
  • NORTH BETHESDA, Md., March 12, 2024 /PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) is pleased to announce the 2024 Facility of the Year Awards (FOYA) submission finalists that met the rigorous qualifications and requirements of the FOYA program.
  • FOYA is the premier global awards program recognizing innovation and creativity in manufacturing facilities that serve the regulated healthcare industry.
  • "The announcement of ISPE's FOYA submission finalists is step one to recognizing and celebrating innovation in pharmaceutical manufacturing plant design and qualification.

ISA Emphasizes How Automation Drives the Global Quest for Resilient Supply Chains in New Position Paper

Retrieved on: 
Tuesday, March 12, 2024
ISA, Welding, Transport, Safety, COVID-19, Workforce, International Society, Intelligence, Education

Durham, North Carolina--(Newsfile Corp. - March 12, 2024) - The International Society of Automation (ISA) - the leading professional society for automation - has announced the publication of a new position paper, " Automation Drives the Global Quest for Resilient Supply Chains. "

Key Points: 
  • Durham, North Carolina--(Newsfile Corp. - March 12, 2024) - The International Society of Automation (ISA) - the leading professional society for automation - has announced the publication of a new position paper, " Automation Drives the Global Quest for Resilient Supply Chains. "
  • In this position paper, ISA explains how the global pandemic and political instability have driven many manufacturers to shift their operations closer to home as they seek to increase efficiencies and reduce supply chain risks.
  • This position paper really showcases the importance of a resilient supply chain, and the important role that automation technologies and professionals play."
  • ISA, as a non-profit international professional organization, offers many resources that help stakeholders prioritize resilient supply chain and other leading issues in automation.